Emcure Pharmaceuticals Ltd (BSE: 544210, NSE: EMCURE) announced its consolidated financial results for the quarter ended September 30, 2025, showcasing strong growth momentum across both domestic and international operations. The domestic segment recorded a 10.6% year-on-year growth, driven by consistent performance across key therapeutic areas and the rollout of new initiatives. The company reiterated its commitment to strengthening its product portfolio and enhancing operational capabilities in the Indian market.
A key highlight for the quarter was Emcure’s strategic collaboration with Novo Nordisk for the launch of Poviztra®, a biological injectable form of semaglutide in India. Under this partnership, Emcure will exclusively manage the distribution, commercialization, and promotion of Poviztra®, indicated for chronic weight management and the reduction of cardiovascular risk in patients with overweight or obesity. Additionally, the company finalized the acquisition of the remaining minority stake in its Zuventus subsidiary, consolidating ownership.
The international business segment maintained its upward trajectory, posting 16% growth during the quarter. The European market surged by 23%, supported by new product launches and the scaling up of operations at Manx. Canada recorded a robust 18% increase, while the Rest of the World (RoW) division sustained steady momentum, particularly in the non-ARV product category.
Commenting on the results, Satish Mehta, CEO and Managing Director of Emcure Pharmaceuticals, stated“Our second quarter delivered solid performance across all business segments. We continue to strengthen our portfolio in key markets through a mix of in-house innovation and strategic partnerships. The Novo Nordisk collaboration positions us strategically in the growing obesity segment, providing early access to a high-potential market. Our focus remains on achieving consistent growth and improving margins across the board.”
Founded in 1981 and headquartered in Pune, India, Emcure Pharmaceuticals Ltd (EPL) is a leading research-driven pharmaceutical company involved in the development, manufacturing, and global marketing of a diverse range of pharmaceutical products. Ranked 12th among Indian pharmaceutical companies by domestic sales (MAT June 2024), Emcure operates in over 70 countries, including major markets across Europe and Canada. The company remains committed to innovation, quality, and patient-centric healthcare solutions that enhance well-being across key therapeutic categories.
